News

Cynvenio Biosystems Co-Founder & Chairman Honored by the Scholarship Foundation of Santa Barbara

May 14, 2012 | Cynvenio Biosystems announced today that Fred Gluck, its co-Founder and Chairman of the Board, will be the recipient of the 2012 South Coast Pioneer Award. Now in its 18th year, the South Coast Business & Technology Awards was designed to honor individuals and organizations who have demonstrated an extraordinary commitment to helping the South Coast of Santa Barbara County remain economically vital.

Cynvenio to Present at the 103rd American Association for Cancer Research (AACR) Annual Meeting on its proprietary Circulating Tumor Cell (CTC) isolation flow cell and the workflow for the analysis of DNA mutations in CTC

March 25, 2012 | Cynvenio Biosystems announced that it will be presenting a poster at the 103rd Annual Meeting of the American Association for Cancer Research taking place at the McCormick Center in Chicago, next week. The presentation will describe Cynvenio’s proprietary Circulating Tumor Cell (CTC) isolation flow cell and the workflow for the analysis of DNA mutations in circulating tumor cells (CTC).

Shape Shift – Biotech firm breaks mold, becomes manufacturer too

March 12, 2012 | LA Business journal article about Cynvenio’s new manufacturing subsidiary, BioMolded Products LLC, launched to make plastic pieces for medical tests and for a blood-processing machine the company plans to unveil later this year. Even more ambitious: Biomolded is making lab equipment for other companies, potentially giving the company a revenue stream while it works to commercialize its cancer tests.

National Cancer Institute Awards Two Lung Cancer Circulating Tumor Cell (CTC) Development Contracts To Cynvenio Biosystems, Inc.

February 7, 2012 | Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research, personalized medicine and the molecular diagnostics of cancer, today announced that the National Cancer Institute (NCI) awarded two Small Business Innovative Research (SBIR) contracts to develop novel lung cancer tests based on the isolation of mutation-bearing Circulating Tumor Cells (CTCs) from whole blood.

News

Cynvenio Biosystems Co-Founder & Chairman Honored by the Scholarship Foundation of Santa Barbara

Cynvenio to Present at the 103rd American Association for Cancer Research (AACR) Annual Meeting on its proprietary Circulating Tumor Cell (CTC) isolation flow cell and the workflow for the analysis of DNA mutations in CTC

Shape Shift – Biotech firm breaks mold, becomes manufacturer too

National Cancer Institute Awards Two Lung Cancer Circulating Tumor Cell (CTC) Development Contracts To Cynvenio Biosystems, Inc.

Valley Struggles to Create Biotech Cluster

Cynvenio Adds Amit Munshi and Simon Raab, Ph.D. to its Board of Directors

Cynvenio Biosystems Selected as a 2011 FiReStarter Company

VC Vision – Shifts Occur as Some Investors’ Tastes Are Changing

Biomagnetic Separations' Abilities Increase

Cynvenio Biosystems, Inc. Expands Core Management Team